Cite
Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth.
MLA
Jiayan Lang, et al. “Targeted Co-Delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth.” ACS Nano, vol. 13, no. 2, Feb. 2019, pp. 2176–89. EBSCOhost, https://doi.org/10.1021/acsnano.8b08823.
APA
Jiayan Lang, Xiao Zhao, Xiuchao Wang, Ying Zhao, Yiye Li, Ruifang Zhao, Keman Cheng, Yao Li, Xuexiang Han, Xiaowei Zheng, Hao Qin, Geranpayehvaghei, M., Jian Shi, Anderson, G. J., Jihui Hao, He Ren, & Guangjun Nie. (2019). Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth. ACS Nano, 13(2), 2176–2189. https://doi.org/10.1021/acsnano.8b08823
Chicago
Jiayan Lang, Xiao Zhao, Xiuchao Wang, Ying Zhao, Yiye Li, Ruifang Zhao, Keman Cheng, et al. 2019. “Targeted Co-Delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth.” ACS Nano 13 (2): 2176–89. doi:10.1021/acsnano.8b08823.